The ErbB1-dependent effect of recombinant epidermal growth factor (rEGF) against lapatinib-induced cytotoxicity in Caco-2 human intestinal cells / Raja Nur Firzanah Syaza Raja Sharin ... [et al.]

• Main Authors: Raja Sharin, Raja Nur Firzanah Syaza, Wan Mohamad Zain, Wan Nor I’zzah, Khan, Jesmine, Ibahim, Mohammad Johari
• Format: Article
• Language: English
• Published: Universiti Teknologi MARA, Pulau Pinang 2022
• Subjects: RC Internal Medicine; Cancer; Research. Experimentation; RG Gynecology and obstetrics; Diseases of the breast
• Online Access: https://ir.uitm.edu.my/id/eprint/68272/1/68272.pdf; https://ir.uitm.edu.my/id/eprint/68272/

Lapatinib, an orally administered dual ErbB1 and ErbB2 tyrosine kinase inhibitor, is an FDA-approved treatment for ErbB2-positive breast tumour. However, diarrhoea is one of the major drawbacks for this treatment. Incidence of lapatinib-induced diarrhoea (LID) has been reported as high as 58-78% of...